Olema Pharmaceuticals jobs

Senior Clinical Trial Associate San Francisco, California Olema Oncology is dedicated to developing better medicines for breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer with blockbuster potential as a monotherapy and in combination in ER+/HER2- metastatic breast cancer. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through the ways in which we fearlessly support, motivate, and challenge one another. At Olema, we know that when we put people first, our work becomes second to none. If you're ready to join us at the edge of something unstoppable, let's make a profound impact together for our patients, for your career, for what's beyond . You can view our latest corporate deck and other presentations here . About the Role >>> Senior Clinical Trial Associate As the Senior Clinical Trial Associate reporting to the Senior Manager, Clinical Trial Leader, you will provide comprehensive administrative and operational support to clinical team members across all study activities, including both in-house and outsourced trials. This role supports cross-functional study execution through coordination with internal teams, external vendors, and site staff, and may include contributing to study documentation such as informed consent forms (ICFs) and central IRB submissions, supporting site payments and other study-related operational activities, as well as liaising with and following up with investigator sites. Responsibilities include assisting with study start-up, maintenance, and closeout activities; managing study documentation and

Lead Senior Medical Writer Boston, Massachusetts Olema Oncology is dedicated to developing better medicines for breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer with blockbuster potential as a monotherapy and in combination in ER+/HER2- metastatic breast cancer. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through the ways in which we fearlessly support, motivate, and challenge one another. At Olema, we know that when we put people first, our work becomes second to none. If you're ready to join us at the edge of something unstoppable, let's make a profound impact together for our patients, for your career, for what's beyond . You can view our latest corporate deck and other presentations here . About the Role >>> Lead Senior Medical Writer As the Lead Senior Medical Writer, reporting to the Director of Medical Writing, you will lead the development, and delivery of high-quality scientific and regulatory documents supporting Olema's oncology portfolio. This role requires strong cross-functional leadership, partnering closely with Clinical Science, Clinical Development, Regulatory Affairs, Biometrics, and other stakeholders to translate complex clinical and preclinical data into clear, accurate, and compelling content for regulatory submissions, medical communications, and scientific publications. In addition, you will drive consistency, quality, and timelines across deliverables, contributing to the overall medical writing strategy and supporting key regulatory and clinical milestones. This role is based out of our Boston,

Senior Director, Marketing San Francisco, California Olema Oncology is dedicated to developing better medicines for breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer with blockbuster potential as a monotherapy and in combination in ER+/HER2- metastatic breast cancer. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through the ways in which we fearlessly support, motivate, and challenge one another. At Olema, we know that when we put people first, our work becomes second to none. If you're ready to join us at the edge of something unstoppable, let's make a profound impact together for our patients, for your career, for what's beyond . You can view our latest corporate deck and other presentations here . About the Role >>> Senior Director, Marketing As the Senior Director, Marketing you will design and execute the Commercial roadmap that enables the successful potential U.S. launch of palazestrant, Olema's lead program currently in Phase 3 for ER+ HER2- metastatic breast cancer. The ideal candidate will have experience in the commercialization of oral oncology therapies in breast cancer and a track record of leading successful oncology drug launches in the US. This role is based out of our San Francisco office and will require travel as needed. Your work will primarily encompass: Building the strategic marketing plan and leading launch readiness initiatives (branding, positioning, messaging platform, story flow and creative imagery)

Associate Director, Analytical Development Boston, Massachusetts Olema Oncology is dedicated to developing better medicines for breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer with blockbuster potential as a monotherapy and in combination in ER+/HER2- metastatic breast cancer. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through the ways in which we fearlessly support, motivate, and challenge one another. At Olema, we know that when we put people first, our work becomes second to none. If you're ready to join us at the edge of something unstoppable, let's make a profound impact together for our patients, for your career, for what's beyond . You can view our latest corporate deck and other presentations here . About the Role >>> Associate Director, Analytical Development As the Associate Director of Analytical Development reporting to the Senior Director of Analytical Chemistry you will be responsible for driving progress of both early and late-stage molecules by delivering phase - appropriate analytical methods, validation and tech transfers. You will partner with cross-functionally supporting process development, formulations, CMC, and quality activities. In addition, you will bring demonstrated team playing and collaboration skills and experience operating effectively in a fast-paced, growth-stage biotech environment. This role can be based out of our San Francisco, CA or Boston, MA office and will require 10-15% travel . Your work will primarily encompass: Supporting analytical method development,

Vice President, Market Access San Francisco, California Olema Oncology is dedicated to developing better medicines for breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer with blockbuster potential as a monotherapy and in combination in ER+/HER2- metastatic breast cancer. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through the ways in which we fearlessly support, motivate, and challenge one another. At Olema, we know that when we put people first, our work becomes second to none. If you're ready to join us at the edge of something unstoppable, let's make a profound impact together for our patients, for your career, for what's beyond . You can view our latest corporate deck and other presentations here . About the Role >>> Vice President, Market Access As the Vice President of Market Access, you will build and lead the market access organization and capabilities critical to Olema's mission to bring better medicines to breast cancer patients. This leader will have a significant role in preparing the company and the market for the launch of Olema's lead product, palazestrant, a novel SERD/CERAN being evaluated in ER+ HER2- metastatic breast cancer. The leadership scope spans all aspects of U.S. market access-payor and account engagement, pricing, coverage and reimbursement, distribution, and patient support programs. The ideal candidate brings deep market access expertise in oral oncology therapeutics and has demonstrated success building

Associate Director, Clinical Supply Chain Boston, Massachusetts Olema Oncology is dedicated to developing better medicines for breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer with blockbuster potential as a monotherapy and in combination in ER+/HER2- metastatic breast cancer. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through the ways in which we fearlessly support, motivate, and challenge one another. At Olema, we know that when we put people first, our work becomes second to none. If you're ready to join us at the edge of something unstoppable, let's make a profound impact together for our patients, for your career, for what's beyond . You can view our latest corporate deck and other presentations here . About the Role >>> Associate Director, Clinical Supply Chain As the Associate Director of Clinical Supply Chain reporting to the Vice President, Clinical Supply Chain, you will plan, create, implement, build, and optimize the clinical supply chain to ensure uninterrupted and timely clinical drug supply for Olema's clinical programs. This role is available in either our San Francisco or Cambridge office and will require about 15% domestic or international travel. Your work will primarily encompass: End to End clinical supply chain management Develop and implement global Clinical Supply Chain strategies Manage global inventories, shipping, and third-party manufacturers / logistics providers Develop and manage Interactive Response Technologies (IRT) systems Oversight packaging,

Vice President Quality Assurance Boston, Massachusetts Olema Oncology is dedicated to developing better medicines for breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer with blockbuster potential as a monotherapy and in combination in ER+/HER2- metastatic breast cancer. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through the ways in which we fearlessly support, motivate, and challenge one another. At Olema, we know that when we put people first, our work becomes second to none. If you're ready to join us at the edge of something unstoppable, let's make a profound impact together for our patients, for your career, for what's beyond . You can view our latest corporate deck and other presentations here . About the Role >>> Vice President, Quality Assurance The Vice President, Quality Assurance serves as the senior leader accountable for defining and driving Olema's global quality strategy, systems, and governance across the full product lifecycle, including clinical development, manufacturing, pharmacovigilance, and commercial. This leader is the primary voice of Quality at the executive level and ensures a phase-appropriate, risk-based approach to quality that reflects the needs of oncology drug development, where patient safety, data integrity, and speed are critical. Operating with appropriate independence, this role partners cross-functionally and leads an established Quality leadership team across GCP, GMP, and GPV - aligning priorities, strengthening execution, and ensuring inspection readiness as Olema advances

Senior Manager, Legal Operations & Contracts San Francisco, California Olema Oncology is dedicated to developing better medicines for breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer with blockbuster potential as a monotherapy and in combination in ER+/HER2- metastatic breast cancer. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through the ways in which we fearlessly support, motivate, and challenge one another. At Olema, we know that when we put people first, our work becomes second to none. If you're ready to join us at the edge of something unstoppable, let's make a profound impact together for our patients, for your career, for what's beyond . You can view our latest corporate deck and other presentations here . About the Role >>> Senior Manager, Legal Operations & Contracts As the Senior Manager, Legal Operations & Contracts reporting to the Vice-President, Legal Counsel, you will bring strong legal operations expertise, including process management, execution, compliance, and process optimization, with a focus on building and scaling efficient workflows. In addition, you bring a deep background in drafting, reviewing, and negotiating a high volume of both routine and complex contracts. This role will operate independently across functions as a trusted partner, proactively managing the end-to-end contract lifecycle for commercialization contracts while driving operational excellence and efficiency. This role will support the legal team through KPI tracking, metrics, and analysis,

Director, CMC Drug Substance Manufacturing Dublin, Ireland Olema Oncology is dedicated to developing better medicines for breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer with blockbuster potential as a monotherapy and in combination in ER+/HER2- metastatic breast cancer. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through the ways in which we fearlessly support, motivate, and challenge one another. At Olema, we know that when we put people first, our work becomes second to none. If you're ready to join us at the edge of something unstoppable, let's make a profound impact together for our patients, for your career, for what's beyond . You can view our latest corporate deck and other presentations here . About the Role >>> Director, CMC Drug Substance Manufacturing As the Director, CMC Drug Substance Manufacturing reporting to the Sr Director, Drug Substance Development and Manufacturing, you will provide technical leadership and hands-on execution to support late-stage development, technology transfer to CDMOs, and commercial readiness including NDA filing for small molecule drug substances. This role is critical to ensuring successful scale-up, validation, and regulatory approval of drug substance processes. The individual will work cross-functionally and externally with CDMOs to deliver robust, compliant, and efficient manufacturing processes suitable for commercial supply. This role is based out of our Dublin, Ireland office and will require 10-15% travel. Your work will primarily encompass:

Associate Strategic Accounts Director, Pharma and Biotech Remote US Rapidly Growing Life Sciences Technology Company Ultima Genomics is a rapidly growing company that is developing ground-breaking genomics technologies. Our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. We have developed a foundational new approach to sequencing at scale that overcomes limitations due to the high costs of current technologies. We are well-funded and have raised approximately $600 million from global top-tier investors. Our team brings together unique and diverse expertise across multiple disciplines, from healthcare and life sciences, to engineering, to technology and software and beyond. We are a collaborative group, including successful entrepreneurs, chemists, hardware and software engineers, genomics and biotechnology experts, molecular and computational biologists, software and algorithm experts, and operations and commercial leaders. Join us to develop and commercialize technologies that unleash the power of genomics at scale and empower the future of human health. We are looking for a highly motivated Associate Strategic Accounts Director, Pharma and Biotech to join our team! You will be a key member of the Strategic Accounts team supporting the VP, Finance and Business Development in executing Ultima's strategy in enabling large-scale data generation and engaging with biotech and pharma accounts. Experience in the life science tools or pharma-services space with a consistent track record of commercial success is highly preferred. This role will report to the VP, Finance and Business Development. How You'll Contribute - Act as

Pharmaceutical Sciences, Technology & Innovation Lead (Sr. Director) Boston, MA posted: Posted Yesterday

Pharmaceutical Sciences, Operations & Performance Lead (Sr. Director) Boston, MA posted: Posted 30+ Days Ago

Principal or Associate Scientist, Analytical Development Japan (Late Stage), Pharmaceutical Sciences Fujisawa, Japan posted: Posted Today

Principal or Associate Scientist, Analytical Development Japan, Pharmaceutical Sciences Fujisawa, Japan posted: Posted 30+ Days Ago

Associate Director or Principal Scientist, Facility Operations, Pharmaceutical Sciences Fujisawa, Japan posted: Posted 30+ Days Ago

Senior Specialist, Regulatory Operations Frederick, MD Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Senior Specialist, Regulatory Operations, will

Pharmaceutical Technician II Singapore, Singapore Embrace the role of a Pharmaceutical Technician II and play a vital role in sterile pharmaceutical production. Operate advanced equipment, ensure GMP compliance, and support quality manufacturing processes. If you have hands-on experience in pharmaceutical manufacturing and a passion for safety and precision, this is your opportunity to make an impact.

Pharmaceutical Technician II Singapore, Singapore Embrace the role of a Pharmaceutical Technician II and play a vital role in sterile pharmaceutical production. Operate advanced equipment, ensure GMP compliance, and support quality manufacturing processes. Ideal for candidates with 1-5 years' experience in pharma, this role offers hands-on work in a dynamic, safety-focused environment. Grow your career in pharmaceutical manufacturing today!

Pharmaceutical Technician II Singapore, Singapore Embrace the role of a Pharmaceutical Technician II and play a vital role in sterile pharmaceutical production. Operate advanced equipment, ensure GMP compliance, and contribute to quality manufacturing. If you have hands-on experience in pharma production and a passion for safety and precision, this is your opportunity to make a difference.

Lead Director, Pharmaceutical Contracting Work at Home, Illinois, United States Join us as Lead Director, Pharmaceutical Contracting and drive high-impact negotiations with major pharmaceutical manufacturers. Shape strategy, foster partnerships, and lead rebate initiatives in a dynamic healthcare environment. If you excel in complex contract negotiations and thrive in leadership roles, this is your opportunity to make a significant impact.

Senior Manager, Total Rewards Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Senior Manager, Total Rewards

Pharmaceutical Technician II Singapore, Singapore Embrace the opportunity to become a Pharmaceutical Technician II and play a vital role in sterile pharmaceutical production. Operate advanced equipment, ensure GMP compliance, and contribute to quality manufacturing. If you have hands-on experience in pharma production and a passion for safety and precision, this is your opportunity to make a difference.

Senior Director of CMC and Nonclinical Program Management North Dartmouth, MA Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix

Thought Leader Liaison (TLL), West Region United States Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Associate Director, Thought